Clinical paper

Corticosteroid use with extracorporeal cardiopulmonary resuscitation for out-of-hospital cardiac arrest: A nationwide observational study

Takaki Hirano, Mikio Nakajima, Hiroyuki Ohbe, Richard H Kaszynski, Yudai Iwasaki, Yuki Arakawa, Yusuke Sasabuchi, Kiyohide Fushimi, Hiroki Matsui, Hideo Yasunaga

Abstract

Aim: Several studies have reported that corticosteroid administration for cardiac arrest patients may improve outcomes. However, these previous studies have not examined the effect of corticosteroid use in out-of-hospital cardiac arrest (OHCA) patients administered extracorporeal cardiopulmonary resuscitation (ECPR). Therefore, we aimed to examine the effectiveness of corticosteroids in OHCA patients administered ECPR.

Methods: Using the Japanese Diagnosis Procedure Combination inpatient database, we included OHCA patients who were administered ECPR on the day of admission between July 2010 and March 2019. The patients were categorized into the corticosteroid and control groups according to whether they received corticosteroids on the day of admission or not. The primary outcome was in-hospital mortality and the secondary outcomes included percentages of neurologically favorable survival, major bleeding complications, and infection-related complications. We compared the outcomes using a propensity score matching analysis.

Results: We identified 6,142 eligible patients (459 vs 5,683, the corticosteroid and control group, respectively). One-to-four propensity score matching analysis (457 vs 1,827) showed in-hospital mortality was significantly higher in the corticosteroid group compared with the control group (82.1% vs 76.6%; risk difference, 5.5%; 95% CI, 1.5 to 9.5%). Neurologically favorable outcomes did not differ between the two groups (13.6% vs 16.9%; risk difference, 3.3%; 95% CI, −6.9 to 0.3%). The percentage of major bleeding complications and infection-related complications did not significantly differ between the two groups.

Conclusions: The results of this study demonstrated that administration of corticosteroids on the day of admission to OHCA patients administered ECPR was associated with increased in-hospital mortality.

Keywords: Cardiac arrest, Corticosteroid, Extracorporeal cardiopulmonary resuscitation

Introduction

Out-of-hospital cardiac arrest (OHCA) is a major public health challenge. Prognosis for OHCA remains poor and the survival rate at the time of hospital discharge is approximately 10% and 2.6% in the United States and Japan, respectively. Extracorporeal cardiopulmonary resuscitation (ECPR) has been added to the armamentarium of life-saving procedures for OHCA patients. Previous studies have shown that ECPR in OHCA patients could improve survival rates at one and twelve months in comparison with conventional CPR.
Several studies have reported that corticosteroid and vasopressin supplementation—in addition to epinephrine—during CPR may improve outcomes for cardiac arrest.\textsuperscript{7–11} A previously conducted population-based retrospective cohort study on OHCA patients in Taiwan showed that corticosteroid administration during CPR may be associated with improved survival-to-admission, survival to hospital discharge, and one-year survival.\textsuperscript{7} A recent randomized controlled trial (RCT) of in-hospital cardiac arrest (IHCA) demonstrated that supplementation of methylprednisolone and vasopressin in addition to epinephrine during CPR, compared with epinephrine alone, improved the rate of return of spontaneous circulation (ROSC).\textsuperscript{9} Two other RCTs examining IHCA showed consistent benefits of methylprednisolone administration during CPR and hydrocortisone administration in post-cardiac arrest shock.\textsuperscript{10,11} In patients with cardiac arrest, adrenal insufficiency and low serum cortisol concentration during and after CPR have been associated with systemic inflammatory response.\textsuperscript{12,13} Given these findings, corticosteroid administration for cardiac arrest patients was hypothesized to help maintain vascular tone and amplify the effects of vasopressors.\textsuperscript{10,11}

No studies, however, have examined the efficacy of corticosteroids for OHCA patients administered ECPR. In the previous RCTs, the targeted patient population was IHCA—and not OHCA—patients. Moreover, the most recent RCT excluded patients administered ECPR.\textsuperscript{9} ECPR may lead to more potent systemic inflammatory responses than conventional CPR due to the added cardiopulmonary bypass (CPB) component of treatment.\textsuperscript{14} Thus, corticosteroids may also be beneficial in patients administered ECPR. Therefore, the present study was designed to examine the effectiveness of corticosteroid use in OHCA patients administered ECPR, using a Japanese nationwide inpatient database.

**Methods**

**Ethical statement**

This study was approved by the Institutional Review Board of The University of Tokyo (approval number 3501-3). The requirement for informed consent was waived due to the anonymous nature of the data. This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines.\textsuperscript{15}

**Data source**

The present study was a retrospective observational analysis using the Japanese Diagnosis Procedure Combination inpatient database. This database includes administrative claims data and discharge abstracts from more than 1,200 acute-care hospitals and covers approximately 90\% of all tertiary-care emergency hospitals in Japan.\textsuperscript{16} The database also includes information on dates of admission and discharge, age, sex, height, weight, ambulance use, primary and secondary diagnosis, comorbidities at admission, complications after admission, surgical and nonsurgical procedures with procedure date, date and dose of drugs, intensive care unit (ICU) admission, level of consciousness at admission and discharge, and discharge status. The primary diagnosis, comorbidities at admission and complication after admission are recorded in accordance with the International Classification of Diseases, 10th Revision (ICD-10) codes and Japanese text.

**Study population**

We identified OHCA patients who were administered ECPR on the day of admission and registered in the database from July 2010 to March 2019. OHCA patients were defined as those who were administered CPR on the day of admission and presented with a Japan Coma Scale (JCS) of 300 at admission.\textsuperscript{5} A JCS of 300 is equivalent to a Glasgow Coma Scale of 3. Exclusion criteria were defined as follows: (1) patients who were aged < 18 years; (2) trauma patients (ICD-10 codes of main diagnoses, SX or TX); (3) patients who underwent resuscitative thoracotomy on the day of admission; (4) patients who underwent cardiac surgery on the day of admission (to exclude use of CPB during cardiac surgery); (5) patients discharged on the day of admission (to avoid immortal time bias);\textsuperscript{17} or (6) missing value of outcomes.

**Variables**

We identified the following variables: age; sex; body mass index (BMI) at admission; comorbidities;\textsuperscript{18} the Charlson comorbidity index;\textsuperscript{19} teaching hospital admission; ICU admission; admission fiscal year; diagnoses;\textsuperscript{20} procedures performed on the day of admission; medications used on the day of admission including corticosteroid, and blood product use. BMI (kg/m\textsuperscript{2}) was categorized as <18.5, 18.5–24.9, 25.0–29.9, ≥30.0, or missing data. The Charlson comorbidity index was calculated with the ICD-10 code-based comorbidities on admission and was categorized as 0, 1, 2, or ≥3.\textsuperscript{18} The ICD-10 codes used to identify comorbidities and diagnoses are shown in Supplementary Table 1.

**Exposure and outcomes**

The main exposure was whether the patient received corticosteroids on the day of admission (corticosteroid group) or did not (control group). Corticosteroid administration was defined as intravenous administration of hydrocortisone, methylprednisolone, prednisolone, betamethasone, and/or dexamethasone regardless of dosage. The dosage of corticosteroids was described in the corticosteroid group. The dosage was converted into methylprednisolone equivalencies.\textsuperscript{21}

The primary outcome was in-hospital mortality. The secondary outcomes were percentages of neurologically favorable survival, major bleeding complications, and infection-related complications. Neurologically favorable survival was defined as patients who were discharged from the hospital with a JCS of 0 or single digit. JCS of 0 or single digit are roughly equivalent to a Cerebral Performance Category score of 1 or 2.\textsuperscript{2,20,22} Major bleeding complications was defined using post-admission complication ICD-10 code as intracranial bleeding (ICD-10 code, I61), intraspinal bleeding (G951), pericardial hematoma (I312), intra-abdominal hematoma or retroperitoneal hematoma (K661), intra-arterial bleeding (M250), intracranial bleeding (H448), and compartment syndrome (M622) during hospitalization.\textsuperscript{23} Infection-related complications were defined as the onset of pneumonia (ICD-10 code, J15 and J18), sepsis (A40, A41, and R65), surgical site infection (T814–6, T827, T857 and T880), urinary tract infection (N30 and N39), and other infections (A04, G00, I31, O86 and Y93).\textsuperscript{24}

**Statistical analysis**

We used propensity score matching analyses to account for the differences in baseline demographics and characteristics between the corticosteroid and control groups. The propensity scores for corticosteroid use on the day of admission were calculated using a multivari-
We identified 6,142 eligible patients during the study period from 445 facilities (Fig. 1). Among these patients, the corticosteroid and control groups consisted of 459 and 5,683 patients, respectively. After a one-to-four propensity score matching, we compared 457 and 5,827 patients in the corticosteroid and control groups, respectively. The C-statistics for the propensity score model was 0.78.

The summary of baseline characteristics before and after propensity score-matching are shown in Table 1. A more comprehensive compilation of the baseline characteristics is shown in Supplementary Table 2. Before propensity score matching, patients in the corticosteroid group were more likely to have a higher percentage of BMI < 18.5, BMI ≥ 30.0, BMI of missing, obstructive lung disease, ICU admission, central venous catheter use coronary angiography, bronchoscopy, renal replacement therapy, temperature modulating device use, tracheostomy, and medications used on the day of admission (dobutamine, norepinephrine, vasopressin, atropine, sodium bicarbonate solution, magnesium sulfate, propofol, and blood products). On the other hand, patients in the corticosteroid group were likely to have a lower percentage of BMI of 18.5–24.9 and 25.0–29.9, hypertension, ventricular fibrillation, acute coronary syndrome, aortic dissection, pulmonary embolism, subarachnoid hemorrhage, defibrillation, percutaneous coronary intervention, and amiodarone use. After propensity score matching, the covariates were balanced between the two groups except for the proportion of BMI of missing, temperature modulating device use, and dopamine use. The median dosage of corticosteroids on the day of admission (converted into methylprednisolone equivalency) in the corticosteroid group was 100 mg (IQR, 40–915 mg).

### Outcomes

The outcomes after propensity score-matching are shown in Table 2. In-hospital mortality was significantly higher in the corticosteroid group compared with the control group (82.1% vs 76.6%; risk difference, 5.5%; 95% CI, 1.5 to 9.5%). Neurologically favorable outcomes did not differ between the two groups (13.6% vs 16.9%; risk difference, −3.3%; 95% CI, −6.9 to 0.3%). The percentage of major bleeding complications did not significantly differ between the two groups (0.9% vs 1.5%; risk difference, −0.7%; 95% CI, −1.7 to 0.4%). The percentage of infection-related complications also did not significantly differ between the two groups (14.7% vs 15.7%; risk difference, −1.0%; 95% CI, −4.6 to 2.7%).

In the sensitivity analysis using overlap weighting, the patient charactersitics after weighting are provided in Supplementary Table 3. Table 3 shows the results of the sensitivity analysis. In-hospital mortality was significantly higher in the corticosteroid group compared with the control group (82.2% vs 76.0%; risk difference, 6.2%; 95% CI, 4.2 to 8.2%). Neurologically favorable outcomes were significantly lower in the corticosteroid group compared with the control group (13.6% vs 18.1%; risk difference, −4.6%; 95% CI, −6.4 to −2.7%). The percentage of major bleeding complications was significantly lower in the corticosteroid group compared with the control group (0.8% vs 1.5%; risk difference, −0.7%; 95% CI, −1.2 to −0.1%). The percentage of infection-related complications did not significantly differ between the two groups (14.5% vs 14.8%; risk difference, −0.3%; 95% CI, −2.0 to 1.5%).

The sensitivity analysis of one-to-four matching, including patients who were discharged on the day of admission, showed similar results to the main analysis with regard to the primary outcome. In-hospital mortality was significantly higher in the corticosteroid group compared with the control group (84.9% vs 79.7%; risk difference, 5.2%; 95% CI, 1.7 to 8.6%). Neurologically favorable outcomes were significantly lower in the corticosteroid group compared with the control group (11.4% vs 15.4%; risk difference, −4.0%; 95% CI, −7.1 to −0.9%). The percentage of major bleeding complications did not significantly differ between the two groups (1.1% vs 1.7%; risk difference, −0.6%; 95% CI, −1.6 to 0.5%). The percentage of infection-related complications also did not significantly differ between the two groups (1.1% vs 1.7%; risk difference, −0.6%; 95% CI, −1.6 to 0.5%).
Discussion

This nationwide observational study focused on the effectiveness of corticosteroid use in OHCA patients who were administered ECPR. The major finding of the present study was that administration of corticosteroids on the day of admission for OHCA patients administered ECPR was associated with increased in-hospital mortality.

The difference in outcomes observed between the present and previous studies could have arisen due to the population targeted in the present study being limited to OHCA patients who were administered ECPR. When it comes to using CPB, our findings are similar to those of several previous RCTs examining the efficacy of corticosteroid use in cardiac surgery with CPB.\textsuperscript{30–32} CPB induces a systemic inflammatory response, which is associated with adverse clinical outcomes.\textsuperscript{14} Although corticosteroids were shown to attenuate this inflammatory response,\textsuperscript{33} three previous RCTs on cardiac surgery using CPB did fail to demonstrate the efficacy of corticosteroids.\textsuperscript{30–32} Several hypotheses were raised as to the reason for these findings.\textsuperscript{31} First, corticosteroid-induced insulin resistance may exacerbate myocardial ischemia by preventing glucose from entering the myocardial cells. Second, the inflammatory response is imperative in the body’s natural ability to heal, however, corticosteroids may impede this process. A previous study reported that corticosteroid use after myocardial infarction increased the infarct size.\textsuperscript{34} While previous RCTs included only 10–30% of patients with a shockable rhythm,\textsuperscript{7–11} the present study included approximately 50% of patients with a shockable rhythm and acute coronary syndrome. Therefore, our study was limited to ECPR cases, which included a large number of patients with cardiogenic cardiac arrest.

On the other hand, a recent RCT reported a lack of hemodynamic benefit associated with corticosteroid administration in IHCA patients.\textsuperscript{35} In this previous study, mean arterial pressure was slightly higher within the first 4 hours post-ROSC in the corticosteroid group; however, this marginal benefit could not be documented at subsequent follow-up. Early resistance to corticosteroids was suggested as a potential cause of these results. A similar—albeit unidentified—underlying mechanism could have influenced the outcome of our study.

The results of this study do not support the recommendation for routine corticosteroid use in OHCA patients administered
The strength of the present study lies in its internal validity utilizing a large nationwide database with several statistical analyses. For the primary outcome, the results were consistent in the main statistical analysis and in the two additional sensitivity analyses. Even though the results of this study were different from previous studies investigating cardiac arrest patients, no RCTs to date have examined the effect of corticosteroids on OHCA patients, nor on OHCA patients administered ECPR cases. Thus, the present study serves as the justification for conducting further RCTs.

| Variables                        | Before propensity score matching | After propensity score matching |
|----------------------------------|---------------------------------|--------------------------------|
|                                  | Control group (n = 5683) | Corticosteroid group (n = 459) | Control group (n = 1827) | Corticosteroid group (n = 457) |
| Age, median (IQR)                | 61 (50, 70) 61 (49, 69) | –8.1 | 59 (48, 70) 61 (49, 69) | 0.0 |
| Male                             | 4558 (80.2) 360 (78.4) | –4.4 | 1390 (76.1) 359 (78.6) | 5.9 |
| Comorbidity                      |                               |     |                               |     |
| Diabetes mellitus                | 697 (12.3) 48 (10.5) | –5.7 | 192 (10.5) 48 (10.5) | 0.0 |
| Hypertension                     | 701 (12.3) 37 (8.1) | –14.2 | 158 (8.6) 37 (8.1) | –2.0 |
| Obstructive lung disease         | 649 (11.4) 86 (18.7) | 20.5 | 378 (20.7) 85 (18.6) | –5.3 |
| Rheumatic disease and vasculitis | 11 (0.2) 2 (0.4) | 4.3 | 7 (0.4) 2 (0.4) | 0.9 |
| Interstitial pneumonia           | 4 (0.1) 1 (0.2) | 3.9 | 7 (0.4) 1 (0.2) | –3.0 |
| Charlson comorbidity index       |                               |     |                               |     |
| 0                                | 2997 (52.7) 237 (51.6) | –2.2 | 1017 (55.7) 236 (51.6) | –8.1 |
| 1                                | 1757 (30.9) 142 (30.9) | 0.0 | 539 (28.9) 142 (28.9) | 3.4 |
| 2                                | 596 (10.5) 47 (10.2) | –0.8 | 159 (8.7) 47 (8.7) | 4.7 |
| ≥3                               | 333 (5.9) 33 (7.2) | 5.4 | 112 (6.1) 33 (6.1) | 4.4 |
| Ventricle fibrillation           | 2918 (51.3) 188 (41.0) | –20.9 | 697 (38.1) 188 (38.1) | 6.1 |
| Ventricle tachycardia            | 302 (5.3) 16 (3.5) | –8.9 | 62 (3.4) 16 (3.4) | 0.6 |
| Acute coronary syndrome          | 3125 (55.0) 205 (44.7) | –20.8 | 771 (41.2) 204 (41.2) | 4.9 |
| Aortic dissection                | 93 (1.6) 2 (0.4) | –11.9 | 5 (0.3) 2 (0.3) | 2.8 |
| Pulmonary embolism               | 375 (6.6) 18 (3.9) | –12.0 | 104 (5.7) 18 (5.7) | –8.2 |
| Subarachnoid hemorrhage          | 109 (1.9) 3 (0.7) | –11.2 | 9 (0.5) 3 (0.5) | 2.2 |
| Procedures performed on the day of admission |                   |     |                               |     |
| Coronary angiography             | 1357 (23.9) 137 (29.8) | 13.5 | 476 (26.1) 137 (26.1) | 8.7 |
| Renal replacement therapy        | 630 (11.1) 137 (29.8) | 47.8 | 474 (25.9) 135 (25.9) | 8.0 |
| Temperature modulating device    | 1688 (29.7) 162 (35.3) | 12.0 | 491 (26.9) 162 (26.9) | 18.6 |
| Defibrillation                   | 3054 (53.7) 217 (47.3) | –12.9 | 859 (47.0) 217 (47.0) | 0.9 |
| Percutaneous coronary intervention | 2688 (47.3) 154 (33.6) | –28.3 | 595 (32.6) 154 (32.6) | 2.4 |
| Intra-aortic balloon pump        | 738 (13.0) 56 (12.2) | –2.4 | 229 (12.5) 56 (12.5) | –0.9 |
| Medications used on the day of admission |                   |     |                               |     |
| Epinephrine                      | 4978 (87.6) 394 (85.8) | –5.2 | 1629 (89.2) 393 (86.0) | –9.6 |
| Dopamine                         | 2026 (35.7) 166 (36.2) | 1.1 | 757 (41.4) 166 (41.3) | –10.5 |
| Dobutamine                       | 1550 (27.3) 151 (32.9) | 12.3 | 650 (35.6) 150 (32.8) | –5.8 |
| Norepinephrine                   | 3226 (56.8) 343 (74.7) | 38.5 | 1382 (75.6) 341 (74.6) | –2.4 |
| Vasopressin                      | 247 (4.3) 105 (22.9) | 56.1 | 373 (20.4) 103 (22.5) | 5.2 |
| Atropine                         | 456 (0.8) 53 (11.5) | 11.9 | 214 (11.7) 53 (11.6) | –0.4 |
| Amiodarone                       | 2835 (49.9) 186 (40.5) | –18.9 | 810 (44.3) 186 (40.4) | –7.4 |
| Transfusions used on the day of admission |                   |     |                               |     |
| Red blood cells                  | 2796 (49.2) 330 (71.9) | 47.7 | 1349 (73.8) 328 (71.8) | –4.6 |
| Fresh frozen plasma              | 2263 (39.8) 278 (60.6) | 42.4 | 1167 (63.9) 276 (60.4) | –7.2 |
| Platelets                        | 392 (6.9) 67 (14.6) | 25.0 | 297 (16.3) 65 (14.2) | –5.7 |
| Albumin                          | 2510 (44.2) 244 (53.2) | 18.1 | 1043 (57.1) 243 (53.2) | –7.9 |

Table 2 – Outcomes after propensity score matching.

| Outcomes                        | Control group (n = 1399/1827) | Corticosteroid group (n = 375/457) | Risk difference | 95% confidence interval | p-value |
|---------------------------------|---------------------------------|-----------------------------------|----------------|-------------------------|---------|
| In-hospital mortality           | 76.6% (375/4957)               | 82.1% (375/457)                   | 5.5%           | (1.5% to 9.5%)          | 0.012   |
| Neurologically favorable outcomes | 16.9% (308/1827)              | 13.6% (62/457)                    | –3.3%          | (–6.9% to 0.3%)         | 0.09    |
| Major bleeding complications    | 1.5% (28/1827)                | 0.9% (4/457)                      | –0.6%          | (–1.7% to 0.4%)         | 0.29    |
| Infection-related complications | 15.7% (286/1827)              | 14.7% (67/457)                    | –1.0%          | (–4.6% to 2.7%)         | 0.60    |

ECPR. The strength of the present study lies in its internal validity utilizing a large nationwide database with several statistical analyses. For the primary outcome, the results were consistent in the main statistical analysis and in the two additional sensitivity analyses. Even though the results of this study were different from previous studies investigating cardiac arrest patients, no RCTs to date have examined the effect of corticosteroids on OHCA patients, nor on OHCA patients administered ECPR cases. Thus, the present study serves as the justification for conducting further RCTs.
The present study has several limitations. First, confounding of indication may have inadvertently occurred. Information on cardiac arrest (i.e., presence of witness, bystander CPR and duration of cardiac arrest) in the pre-hospital setting and vital signs after ROSC were unavailable due to the nature of the administrative database. Therefore, the patients with unstable hemodynamics and poor general condition may have favorably received corticosteroids. Second, detailed information on timing and purpose of corticosteroids were unavailable. In particular, it was unclear whether corticosteroids were administered during CPR or after ROSC. However, efficient circulation would be re-established within a relatively short interval after arrival at the hospital because the patients in the present study were limited to those who were administered ECPR. Thus, the percentage of cases involving corticosteroid use during CPR (prior to establishing extracorporeal circulation) would be limited. Although the history of corticosteroid medication prior to admission was also unavailable due to the nature of the database, we obtained surrogate variables of past medical history indicative of prior corticosteroid use. Third, defining ECPR in OHCA patients using procedure codes may lead to misclassification. We defined ECPR cases as patients who received CPR and were placed on extracorporeal life support on the day of admission. We also defined OHCA cases as patients who received CPR and were placed on extracorporeal life support on the day of admission. Therefore, the definition adopted in our study may encompass patients placed on extracorporeal life support due to heart failure after ROSC but not cardiac arrest. The same may also be true for cases involving the use of veno-venous extracorporeal membrane oxygenation due to respiratory failure after cardiac arrest.

Conclusions

This nationwide observational study revealed that administration of corticosteroids on the day of admission to OHCA patients administered ECPR was associated with increased in-hospital mortality. The results of this study do not support the recommendation for routine corticosteroid use in OHCA patients administered ECPR. Although we adjusted for numerous confounding factors via the propensity score method, randomized controlled trials are warranted to confirm our findings.

Conflicts of Interest

The authors declare that they have no conflict of interest.

Acknowledgments

None.

Table 3 – Outcomes after overlap weighting.

| Outcomes                        | Control group | Corticosteroid group | Risk difference (95% confidence interval) | p-value |
|---------------------------------|---------------|----------------------|------------------------------------------|---------|
| In-hospital mortality           | 76.0% (2327/3064) | 82.2% (2529/3078) | 6.2% (4.2% to 8.2%) | <0.001  |
| Neurologically favorable outcomes | 18.1% (556/3064) | 13.6% (418/3078) | -4.6% (-6.4% to -2.7%) | <0.001  |
| Major bleeding complications    | 1.5% (47/3063) | 0.8% (26/3079) | -0.7% (-1.2% to -0.1%) | 0.013   |
| Infection-related complications | 14.8% (452/3064) | 14.5% (446/3079) | -0.3% (-2.0% to 1.5%) | 0.77    |

The Ethics approval and consent to participate

This study was approved by the Institutional Review Board at The University of Tokyo (Approval number 3501-3, December 2017). The requirement for informed consent was waived due to the anonymous nature of the data.

Role of the funding source

This work was supported by grants from the Ministry of Health, Labour and Welfare, Japan (21AA2007 and 22AA2003) and the Ministry of Education, Culture, Sports, Science and Technology, Japan (20H03907).

Appendix A. Supplementary material

Supplementary material to this article can be found online at https://doi.org/10.1016/j.resplu.2022.100308.

References

1. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation 2019;139:e56-e528.
2. Nakajima M, R HK, Goto H, Matsui H, Fushimi K, Yamaguchi Y, et al. Current trends and outcomes of extracorporeal cardiopulmonary resuscitation for out-of-hospital cardiac arrest in Japan: A nationwide observational study. Resusc Plus 2020;4:100048.

3. Hayashida K, Tagami T, Fukuda T, Suzuki M, Yonemoto N, Kondo Y, et al. Mechanical Cardiopulmonary Resuscitation and Hospital Survival Among Adult Patients With Nontraumatic Out-of-Hospital Cardiac Arrest Attending the Emergency Department: A Prospective, Multicenter, Observational Study in Japan (SOS-KANTO [Survey of Survivors after Out-of-Hospital Cardiac Arrest in Kanto Area] 2012 Study). J Am Heart Assoc 2017;6.

4. Ortega-Deballon I, Hornby L, Shemie SD, Bhanji F, Guadagno E. Extracorporeal resuscitation for refractory out-of-hospital cardiac arrest in adults: A systematic review of international practices and outcomes. Resuscitation 2016;101:12–20.

5. Kim SJ, Kim HJ, Lee HY, Ahn HS, Lee SW. Comparing extracorporeal cardiopulmonary resuscitation with conventional cardiopulmonary resuscitation: A meta-analysis. Resuscitation 2016;103:106–16.

6. Sakamoto T, Morimura N, Nagao K, Asai Y, Yokota H, Narita S, et al. Extracorporeal cardiopulmonary resuscitation versus conventional cardiopulmonary resuscitation in adults with out-of-hospital cardiac arrest: a prospective observational study. Resuscitation 2014;85:762–8.

7. Tsai MS, Chuang PY, Yu PH, Huang CH, Tang CH, Chang WT, et al. Glucocorticoid use during cardiopulmonary resuscitation may be beneficial for cardiac arrest. Int J Cardiol 2016;222:629–35.

8. Tsai MS, Huang CH, Chang WT, Chen WJ, Hsu CY, Hsieh CC, et al. The effect of hydrocortisone on the outcome of out-of-hospital cardiac arrest patients: a pilot study. Am J Emerg Med 2007;25:318–25.

9. Andersen LW, Isbye D, Kjaergaard J, Kristensen CM, Darling S, Zwilier ST, et al. Effect of Vasopressin and Methylprednisolone vs Placebo on Return of Spontaneous Circulation in Patients With In-Hospital Cardiac Arrest: A Randomized Clinical Trial. JAMA 2021;326:1586–94.

10. Mentzelopoulos SD, Malachias S, Chamos C, Konstantopolous D, Ntaidou T, Papastylionau A, et al. Vasopressin, steroids, and epinephrine and neurologically favorable survival after in-hospital cardiac arrest: a randomized clinical trial. JAMA 2013;310:270–9.

11. Mentzelopoulos SD, Zakythinos SG, Tzoufi M, Katsios N, Papastylionau A, Gkisioti S, et al. Vasopressin, epinephrine, and corticosteroids for in-hospital cardiac arrest. Arch Intern Med 2009;169:15–24.

12. Adrie C, Adib-Conquy M, Laurent I, Monchi M, Vinsonnement C, Fitting C, et al. Successful cardiopulmonary resuscitation after cardiac arrest as a “sepsis-like” syndrome. Circulation 2002;106:562–8.

13. Hekimian G, Baugnon T, Thuong M, Monchi M, Dabbane H, Jaby D, et al. Cortisol levels and adrenal reserve after successful cardiac arrest resuscitation. Shock 2004;22:116–9.

14. Paparella D. Cardiopulmonary bypass induced inflammation: pathophysiology and treatment. An update. Eur J Cardio-Thorac Surg 2002;21:232–44.

15. Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann Intern Med 2007;147:W163–94.

16. Yasunaga H. Real World Data in Japan: Chapter II The Diagnosis Procedure Combination Database. Ann Clin Epidemiol 2019;1:76–9.

17. Suiisa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 2008;167:492–9.

18. Jo T, Yasunaga H, Yamauchi Y, Mitani A, Hiraishi Y, Hasegawa W, et al. Inhaled corticosteroid withdrawal may improve outcomes in elderly patients with COPD exacerbation: a nationwide database study. ERJ Open Res 2020;6.

19. Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 2011;173:676–82.

20. Ohbe H, Ogura T, Matsuhi H, Yasunaga H. Extracorporeal cardiopulmonary resuscitation for acute aortic dissection during cardiac arrest: A nationwide retrospective observational study. Resuscitation 2020;156:237–43.

21. Liu D, Ahmed A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol 2013;9:30.